Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
225 Clinical Updates found
David Aggen
Groundbreaking Advances for Patients with Muscle-Invasive Bladder Cancer and More to Come

A new era in the treatment of MIBC is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard of care in the perioperative treatment of cisplatin-ineligible or cisplatin-refusing patients. MSK’s David Aggen, MD, discusses this, and what new treatment approaches physicians and scientists at MSK are now testing.
ESMO 2025 Research Roundup: MSK Presents Exciting Advances in Medical Oncology Research
ESMO 2025 Research Roundup: MSK Presents Exciting Advances in Medical Oncology Research

MSK researchers presented exciting advances in medical oncology for a range of cancer types at the ESMO Congress 2025. Highlights included the latest updates on three phase 1 trials testing innovative treatment approaches for select patients with advanced solid tumors, NSCLC, and pancreatic cancer. MSK researchers also presented new insights about mismatch repair deficient solid tumors that may inform tailoring personalized treatments.
Lior Braunstein
Tailoring Adjuvant Therapy for Younger Patients with Low-Risk Breast Cancer

When considering adjuvant therapy preferences for younger patients ages 50 to 69 with early-stage, low genomic risk breast cancer, is it reasonable to omit radiotherapy or endocrine therapy after lumpectomy? A large retrospective cohort study at MSK found that locoregional recurrence rates were significantly lower for those who completed at least one form of adjuvant therapy after lumpectomy.
MSK ASTRO 2025 News: Proton Beam Radiotherapy is Superior to Photon Beam Radiotherapy in Head and Neck Cancer
Proton Beam Reduces Acute Toxicities Compared to IMRT for Head and Neck Cancer Patients Who Receive Unilateral Radiation

Proton beam radiotherapy resulted in similar oncologic outcomes with less toxicity and improved quality of life than photon beam radiotherapy in patients with head and neck cancers, according to results of an MSK-led clinical trial presented today at the 2025 American Society for Radiation Oncology Annual Meeting.
MSK Kids: Recent Research Advances for High-Risk Neuroblastoma
MSK Kids: Recent Research Advances for High-Risk Neuroblastoma

MSK Kids is continuously investigating new ways to improve outcomes and the quality of life for pediatric patients with high-risk neuroblastoma. In this article we detail highlights of the latest clinical and molecular research advances for pediatric neuroblastoma.
Select Patients With Early-Stage Breast Cancer May Safely Skip Post-Mastectomy Nodal Irradiation
Select Patients With Early-Stage Breast Cancer May Safely Skip Post-Mastectomy Nodal Irradiation

Patients with early-stage, node-positive breast cancer whose nodes are pathologically tumor-free after neoadjuvant chemotherapy may safely skip post-mastectomy nodal irradiation without increasing the risk of invasive breast cancer recurrence or death, according to results from a clinical trial published recently in NEJM.
MSK Head and Neck Cancer: Thyroid Cancer Research Update Add to Default shortcuts Primary tabs View Edit Outline Delete Revisions Dynamic Yield Usage Convert Bundle Clone MSK
MSK Head and Neck Cancer: Thyroid Cancer Research Update

Clinicians and scientists at MSK continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include, the safety and feasibility of active surveillance for certain patients, the identification of mutation profiles of subgroups, recommendations for future clinical trials of redifferentiation therapy, and study results showing that larotrectinib may be beneficial for treatment-naïve patients with NTRK fusion-positive thyroid cancer.
Three Decades in the Making: Advancing Rectal MRI at MSK
Three Decades in the Making: Advancing Rectal MRI at MSK

In this Q&A we discuss MSK’s pioneering work in rectal MRI, how it differs from endorectal ultrasound (ERUS), its role in groundbreaking clinical trials for patients with rectal cancer, why expertise matters, and new frontiers for future improvements to rectal MRI.
Neoadjuvant and Adjuvant Pembrolizumab with Standard-of-Care Significantly Improves Event-Free Survival in Head and Neck Cancer
Neoadjuvant and Adjuvant Pembrolizumab with Standard-of-Care Significantly Improves Event-Free Survival in Head and Neck Cancer

Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor, according to a new study published today in The New England Journal of Medicine.
Doctor and patient shaking hands
ASCO 2025 Research Roundup: MSK Presents Practice-Changing Advances in Cancer Research

MSK researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting.Highlights included breakthroughs for patients with advanced gastric cancer, lung cancer, Lynch syndrome-related cancer and salivary gland cancer. Additionally, the first-ever CAR T cell trial for patients with light chain amyloidosis is showing promising results.